| Xiong, Bin |
NCT06117735: Clinical Study of PTFE Covered Stent for Treating Portal Hypertension |
|
|
| Recruiting | N/A | 177 | RoW | Transjugular Intrahepatic Portosystemic shunt | Enlight Medical Technologies (Shanghai) Co., Ltd | Portal Hypertension | 12/25 | 06/26 | | |
| Wang, Fei |
NCT04851613: Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer |
|
|
| Recruiting | 3 | 256 | US, RoW | Afuresertib, Fulvestrant, Afuresertib/placebo | Laekna Limited | Breast Cancer | 10/26 | 12/26 | | |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT05369078: Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects |
|
|
| Recruiting | 1 | 16 | RoW | THR-1442 20mg Single dose, THR-1442 20mg Multiple dose group | Newsoara Biopharma Co., Ltd. | T2DM (Type 2 Diabetes Mellitus) | 05/22 | 05/22 | | |
FLAT, NCT03805191: A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients |
|
|
| Recruiting | N/A | 900 | RoW | | Qilu Hospital of Shandong University, Bayer | Type 2 Diabetes Mellitus, Poor Glycemic Control | 11/20 | 12/22 | | |
NCT05774288: Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders. |
|
|
| Recruiting | N/A | 244 | RoW | Cera™ patent foramen ovale occluders, Another patent foramen ovale occluders | Lifetech Scientific (Shenzhen) Co., Ltd. | Patent Foramen Ovale, Cryptogenic Stroke | 04/25 | 06/29 | | |
| Tao, Weiping |
| Active, not recruiting | 3 | 466 | Europe, Canada, Japan, US, RoW | tucatinib, ONT-380, placebo, T-DM1, Kadcyla | Seagen Inc., Seagen Inc., Seattle Genetics, Inc., Seagen Inc | HER2-positive Breast Cancer | 06/23 | 10/27 | | |
|
|
| Completed | 3 | 275 | RoW | GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant | Genor Biopharma Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 12/22 | 03/24 | | |
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer |
|
|
| Recruiting | 3 | 350 | RoW | GB491 combined with Letrozole, Placebo combined with Letrozole | Genor Biopharma Co., Ltd. | Breast Cancer | 01/26 | 01/27 | | |
NCT04600947: Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma |
|
|
| Not yet recruiting | 2 | 69 | RoW | LP002 | Taizhou HoudeAoke Biomedical Co., Ltd. | Primary Mediastinal Large B-Cell Lymphoma (PMBCL) | 05/22 | 05/23 | | |
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma |
|
|
| Recruiting | 2 | 185 | RoW | HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor | Hutchison Medipharma Limited | Marginal Zone Lymphoma, Follicular Lymphoma | 04/24 | 12/24 | | |
NCT05033132: A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer |
|
|
| Withdrawn | 2 | 177 | RoW | Balstilimab, Balstilimab + Zalifrelimab | Agenus Inc., Betta Pharmaceuticals Co., Ltd. | Cervical Cancer | 12/24 | 12/24 | | |
